EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitSystematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Androgen Receptor Expression in Urothelial Bladder Cancer—A Systematic Review and Meta‐Analysis

Alex Buckby iD, Mandana Gholami, Matthew Hong, Michael O'Callaghan

ANZ Journal of Surgery · 2026-05-21

DOI: 10.1111/ans.70752 ↗

At a glance

Übersichtsarbeit in ANZ Journal of Surgery, published online on 2026-05-21. Written by Alex Buckby and 3 co-authors. Institution: Flinders University, College of Medicine and Public Health, Adelaide, South Australia, Australia. 85 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Bladder cancer is a globally prevalent malignancy with a marked male predominance. Over the past decade, the androgen receptor has been investigated as a potential contributor to bladder cancer pathophysiology. Androgen receptor expression is most commonly assessed via immunohistochemistry, but its association with pathological features and clinical outcomes remains uncertain. This meta‐analysis aimed to evaluate whether androgen receptor expression assessed by immunohistochemistry is associated with pathological characteristics of urothelial bladder cancer, with exploratory assessment of reported prognostic outcomes.

Methods

A systematic search of MEDLINE, EMBASE and Cochrane was performed between January 1st 2000 and October 31st 2024. Papers comparing AR expression using immunohistochemistry to bladder urothelial cancer specimens stratified by grade, stage, gender and survival outcomes were included.

Results

In total 16 papers were included with 2108 patient samples. No correlation was found between androgen receptor expression and grade (OR 0.83, 95% CI 0.43–1.59), stage (OR 0.94, 95% CI 0.38–2.35), progression free survival (HR 0.84, 95% CI 0.45–1.59) or recurrence free survival (HR 0.81, 95% CI 0.49–1.31). Male bladder cancer specimens were more likely to express the androgen receptor than female bladder cancer specimens (OR 1.40, 95% CI 1.03–1.89).

Conclusion

Immunohistochemistry as a measure of androgen receptor expression does not show a consistent association with pathological features and demonstrates no reproducible prognostic signal in the available literature. Male bladder cancer specimens express AR more frequently than female bladder cancer specimens. The significance of this needs to be correlated to further research into normal androgen receptor expression patterns in the urinary bladder and more precise measures of androgen receptor activity than immunohistochemistry.

Subjects

Author keywords

androgenneoplasm gradingneoplasm stagingreceptorssex characteristicsurinary bladder neoplasms

Authors and institutions

  • Flinders University, College of Medicine and Public Health, Adelaide, South Australia, Australia.
  • Department of Urology, Southern Adelaide Local Health Network, Flinders Medical Centre, 1 Flinders Drive, Bedford Park, South Australia, Australia.
  • The University of Adelaide, Discipline of Medicine, Adelaide, South Australia, Australia.

ORCID profiles: Alex Buckby

Cite

APA

Buckby, A., Gholami, M., Hong, M., & O'Callaghan, M. (2026). Androgen Receptor Expression in Urothelial Bladder Cancer—A Systematic Review and Meta‐Analysis. ANZ Journal of Surgery. https://doi.org/10.1111/ans.70752

Vancouver

Buckby A, Gholami M, Hong M, O'Callaghan M. Androgen Receptor Expression in Urothelial Bladder Cancer—A Systematic Review and Meta‐Analysis. ANZ Journal of Surgery. 2026. doi:10.1111/ans.70752

BibTeX
@article{Buckby2026,
  author = {Buckby, Alex and Gholami, Mandana and Hong, Matthew and O'Callaghan, Michael},
  title = {Androgen Receptor Expression in Urothelial Bladder Cancer—A Systematic Review and Meta‐Analysis},
  journal = {ANZ Journal of Surgery},
  year = {2026},
  doi = {10.1111/ans.70752}
}
Start for free →